Medicine
Lansoprazole 30 mg orally disintegrating tablet
Lansoprazole 30 mg orally disintegrating tablet is a generic prescription medicine for oral use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F).
Key facts
- Active ingredient (INN)
- Lansoprazole
- Brand
- Sold under the generic name
- Strength
- 30 mg
- Dosage form
- Orally disintegrating tablet
- Route
- Oral
- Packs
- 10 blister pack
- Manufacturer
- Zydus LifesciencesIndia
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A02BC03 Lansoprazole
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 30 November 2018
- Identifiers
- RxCUI 351260, 351261DailyMed set ID 76ffd38e-bea8-45a0-b6bd-82f0043ce64d, 9b3869ad-f2f7-4954-b75c-5c23b8951635NDC 70771-1133, 68382-772Application ANDA200816
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 10 blister pack in 1 carton / 10 tablet, orally disintegrating in 1 blister pack | 68382-772-77 | Zydus LifesciencesIndia | 30 November 2018 |
| 10 blister pack in 1 carton / 10 tablet, orally disintegrating in 1 blister pack | 70771-1133-4 | Zydus LifesciencesIndia | 30 November 2018 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 10 May 1995 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Lansoprazole
Clinical summary
Lansoprazole is a proton pump inhibitor indicated for the treatment of active duodenal ulcer in adults, among other approved uses. It is available as delayed-release capsules, delayed-release orally disintegrating tablets and orally disintegrating tablets. MedsAcross supplies Lansoprazole for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LansoprazoleFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Prevacid prescribing information (Takeda Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Lansoprazole 30 mg orally disintegrating tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.